{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:24:38Z","timestamp":1791771878669,"version":"4.3.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":732,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1111\/bjd.12389","type":"journal-article","created":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T03:32:49Z","timestamp":1366601569000},"page":"660-665","source":"Crossref","is-referenced-by-count":128,"title":["<i>HLA-B*58:01<\/i>is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population"],"prefix":"10.1093","volume":"169","author":[{"given":"M.","family":"Gon\u00e7alo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Coutinho","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology; Coimbra University Hospital; Praceta Mota Pinto; P-3000-075; Coimbra; Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology; Coimbra University Hospital; Praceta Mota Pinto; P-3000-075; Coimbra; Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Gameiro","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology; Coimbra University Hospital; Praceta Mota Pinto; P-3000-075; Coimbra; Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Brites","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology; Coimbra University Hospital; Praceta Mota Pinto; P-3000-075; Coimbra; Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nunes","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory; Histocompatibility Center of Coimbra; Coimbra; Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martinho","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory; Histocompatibility Center of Coimbra; Coimbra; Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,8,30]]},"reference":[{"key":"10.1111\/bjd.12389-BIB0001|bjd12389-cit-0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/bjd.12389-BIB0002|bjd12389-cit-0002","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1111\/bjd.12389-BIB0003|bjd12389-cit-0003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12389-BIB0004|bjd12389-cit-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000335612","article-title":"Epidemiology of cutaneous adverse drug reactions","volume":"97","author":"Mockenhaupt","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1111\/bjd.12389-BIB0005|bjd12389-cit-0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2230.2010.03922.x","article-title":"Cutaneous adverse drug reactions in a hospital-based Chinese population","volume":"36","author":"Huang","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.12389-BIB0006|bjd12389-cit-0006","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1445-5994.2011.02567.x","article-title":"Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?","volume":"42","author":"Lee","year":"2012","journal-title":"Intern Med J"},{"key":"10.1111\/bjd.12389-BIB0007|bjd12389-cit-0007","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1468-3083.2011.04313.x","article-title":"Cutaneous adverse drug reactions to allopurinol: 10\u00a0year observational survey of the dermatology department - Cagliari University (Italy)","volume":"26","author":"Atzori","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12389-BIB0008|bjd12389-cit-0008","first-page":"403","article-title":"S\u00edndrome de Stevens-Johnson e necr\u00f3lise epid\u00e9rmica t\u00f3xica - casu\u00edstica de 10 anos","volume":"69","author":"Brinca","year":"2011","journal-title":"Rev Soc Port Dermatol Venereol"},{"key":"10.1111\/bjd.12389-BIB0009|bjd12389-cit-0009","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4168\/aair.2012.4.5.309","article-title":"A case of allopurinol-induced fixed drug eruption confirmed with a lymphocyte transformation test","volume":"4","author":"Kim","year":"2012","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1111\/bjd.12389-BIB0010|bjd12389-cit-0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/15569527.2011.554481","article-title":"Allopurinol hypersensitivity syndrome with acute generalized exanthematous pustulosis manifestations","volume":"30","author":"Teo","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1111\/bjd.12389-BIB0011|bjd12389-cit-0011","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/9781841848570-10","volume-title":"Dermatotoxicology","author":"Gon\u00e7alo","year":"2012","edition":"8"},{"key":"10.1111\/bjd.12389-BIB0012|bjd12389-cit-0012","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1111\/bjd.12389-BIB0013|bjd12389-cit-0013","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1398-9995.2011.02677.x","article-title":"NKp46+ cells express granulysin in multiple cutaneous adverse drug eruptions","volume":"66","author":"Schlapbach","year":"2011","journal-title":"Allergy"},{"key":"10.1111\/bjd.12389-BIB0014|bjd12389-cit-0014","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2133.2012.10921.x","article-title":"Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome","volume":"147","author":"Saito","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12389-BIB0015|bjd12389-cit-0015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.aids.0000171414.99409.fb","article-title":"Clinical and immunogenetic correlates of abacavir hypersensitivity","volume":"19","author":"Phillips","year":"2005","journal-title":"AIDS"},{"key":"10.1111\/bjd.12389-BIB0016|bjd12389-cit-0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03256308","article-title":"Successful translation of pharmacogenetics into the clinic: the abacavir example","volume":"13","author":"Phillips","year":"2009","journal-title":"Mol Diagn Ther"},{"key":"10.1111\/bjd.12389-BIB0017|bjd12389-cit-0017","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.12389-BIB0018|bjd12389-cit-0018","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12389-BIB0019|bjd12389-cit-0019","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.12389-BIB0020|bjd12389-cit-0020","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12389-BIB0021|bjd12389-cit-0021","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1111\/bjd.12389-BIB0022|bjd12389-cit-0022","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/bjd.12389-BIB0023|bjd12389-cit-0023","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.12.89","article-title":"HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese","volume":"13","author":"Cao","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1111\/bjd.12389-BIB0024|bjd12389-cit-0024","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12389-BIB0025|bjd12389-cit-0025","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1111\/bjd.12389-BIB0026|bjd12389-cit-0026","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/bjd.12389-BIB0027|bjd12389-cit-0027","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France.","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Th\u00e9rapie"},{"key":"10.1111\/bjd.12389-BIB0028|bjd12389-cit-0028","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12389-BIB0029|bjd12389-cit-0029","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"10.1111\/bjd.12389-BIB0030|bjd12389-cit-0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1034\/j.1600-0536.2001.450601.x","article-title":"Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions","volume":"45","author":"Barbaud","year":"2001","journal-title":"Contact Dermatitis"},{"key":"10.1111\/bjd.12389-BIB0031|bjd12389-cit-0031","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0536.2009.01659.x","article-title":"Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS)","volume":"62","author":"Santiago","year":"2010","journal-title":"Contact Dermatitis"},{"key":"10.1111\/bjd.12389-BIB0032|bjd12389-cit-0032","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.79","article-title":"Phenotype standardization for immune-mediated drug-induced skin injury","volume":"89","author":"Pirmohamed","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/bjd.12389-BIB0033|bjd12389-cit-0033","first-page":"541","article-title":"S\u00edndrome de hipersensibilidade a f\u00e1rmacos\/DRESS: 5 anos de experi\u00eancia num Servi\u00e7o de Dermatologia","volume":"66","author":"Santiago","year":"2008","journal-title":"Trab Soc Port Dermatol Venereol"},{"key":"10.1111\/bjd.12389-BIB0034|bjd12389-cit-0034","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2217\/pgs.11.131","article-title":"Allopurinol pharmacogenetics: assessment of potential clinical usefulness","volume":"12","author":"Zineh","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1111\/bjd.12389-BIB0035|bjd12389-cit-0035","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/bjd.12389-BIB0036|bjd12389-cit-0036","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/bjd.12389-BIB0037|bjd12389-cit-0037","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/bjd.12389-BIB0038|bjd12389-cit-0038","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-010611-134701","article-title":"Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex","volume":"52","author":"Bharadwaj","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/bjd.12389-BIB0039|bjd12389-cit-0039","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/all.12008","article-title":"Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA","volume":"67","author":"Yun","year":"2012","journal-title":"Allergy"},{"key":"10.1111\/bjd.12389-BIB0040|bjd12389-cit-0040","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class-I restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"10.1111\/bjd.12389-BIB0041|bjd12389-cit-0041","unstructured":"Yun J Yerly D Fontana S Pichler W Generation of allopurinol\/oxypurinol specific T cells in vitro Drug Hypersensitivity Meeting DHM5 2012 126 7"},{"key":"10.1111\/bjd.12389-BIB0042|bjd12389-cit-0042","unstructured":"Lin C Chen Y Hung S The pathogenic role of HLA-B*5801 in allopurinol-induced severe cutaneous adverse reactions Drug Hypersensitivity Meeting DHM5 2012 125"},{"key":"10.1111\/bjd.12389-BIB0043|bjd12389-cit-0043","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2230.1998.00311.x","article-title":"Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol","volume":"23","author":"Hamanaka","year":"1998","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.12389-BIB0044|bjd12389-cit-0044","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1586\/eci.12.31","article-title":"T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction","volume":"8","author":"Ko","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1111\/bjd.12389-BIB0045|bjd12389-cit-0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2133\/dmpk.DMPK-11-RV-116","article-title":"A recent update of pharmacogenomics in drug-induced severe skin reactions","volume":"27","author":"Wei","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/bjd.12389-BIB0046|bjd12389-cit-0046","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1399-0039.2011.01649.x","article-title":"Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity","volume":"78","author":"Kostenko","year":"2011","journal-title":"Tissue Antigens"},{"key":"10.1111\/bjd.12389-BIB0047|bjd12389-cit-0047","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bjd.12097","article-title":"Detection of HLA-B*58:01, the susceptible allele for allopurinol induced hypersensitivity, by loop-mediated isothermal amplification","volume":"168","author":"Kwok","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12389-BIB0048|bjd12389-cit-0048","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1759720X11416405","article-title":"Efficacy and safety of febuxostat in patients with hyperuricemia and gout","volume":"3","author":"Garcia-Valladares","year":"2011","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1111\/bjd.12389-BIB0049|bjd12389-cit-0049","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharma.2012.02.003","article-title":"Gout: an overview of available urate lowering therapies","volume":"70","author":"Richette","year":"2012","journal-title":"Ann Pharm Fr"},{"key":"10.1111\/bjd.12389-BIB0050|bjd12389-cit-0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3899\/jrheum.120803","article-title":"HLA-B*5801 should be used to screen for risk of Stevens-Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy","volume":"40","author":"Lee","year":"2013","journal-title":"J Rheumatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12389","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12389\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:05:17Z","timestamp":1676383517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/169\/3\/660\/6615172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,30]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12389","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8,30]]}}}